Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-Transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Ruxolitinib (Primary) ; Fludarabine; Melphalan; Sirolimus; Tacrolimus; Tacrolimus
- Indications Myelofibrosis
- Focus Adverse reactions
- 05 Dec 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 Planned End Date changed from 16 Nov 2022 to 16 Nov 2023.
- 02 Nov 2021 Planned End Date changed from 5 Oct 2021 to 16 Nov 2022.